

# Stefan Sturm

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9511152/publications.pdf>

Version: 2024-02-01

8

papers

123

citations

1937685

4

h-index

1720034

7

g-index

8

all docs

8

docs citations

8

times ranked

265

citing authors

#	ARTICLE	IF	CITATIONS
1	A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a <i>SMN2</i> splicing modifier. British Journal of Clinical Pharmacology, 2019, 85, 181-193.	2.4	75
2	Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer's disease and elderly controls after oral administration of sebragiline. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 382-391.	6.4	21
3	Results and evaluation of a first-in-human study of RG7342, an mGlu5 positive allosteric modulator, utilizing Bayesian adaptive methods. British Journal of Clinical Pharmacology, 2018, 84, 445-455.	2.4	12
4	Metabolism, Excretion, and Pharmacokinetics of [14C]-Radiolabeled Alogliptazir: A Phase I, Nonrandomized, Open-Label, Single-Center, Single-Dose Study in Healthy Male Volunteers. Clinical Therapeutics, 2012, 34, 420-429.	2.5	6
5	Pharmacologic effects of oseltamivir in immunocompromised adult patients as assessed by population PK/PD analysis and drug-disease modelling for dosing regimen optimization. British Journal of Clinical Pharmacology, 2021, 87, 1359-1368.	2.4	4
6	Pharmacokinetics and Pharmacodynamics of Conventional-Dose vs Triple-Dose Oseltamivir in Severely Immunocompromised Children With Influenza. Open Forum Infectious Diseases, 2019, 6, ofz430.	0.9	3
7	No Evidence of QT Prolongation With Supratherapeutic Doses of Alogliptazir. Journal of Cardiovascular Pharmacology, 2012, 59, 288-297.	1.9	2
8	Dosing regimen optimisation for oseltamivir in immunocompromised paediatric patients with influenza: Extrapolation of efficacy. British Journal of Clinical Pharmacology, 2021, , .	2.4	0